Lifeboat Foundation

Biotechnology is a curious marriage of two seemingly disparate worlds. On one end, we have living organisms—wild, unpredictable celestial creations that can probably never be understood or appreciated enough, while on the other is technology—a cold, artificial entity that exists to bring convenience, structure and mathematical certainty in human lives. The contrast works well in combination, though, with biotechnology being an indispensable part of both healthcare and medicine. In addition to those two, there are several other applications in which biotechnology plays a central role—deep-sea exploration, protein synthesis, food quality regulation and preventing environmental degradation. The increasing involvement of AI in biotechnology is one of the main reasons for its growing scope of applications.

So, how exactly does AI impact biotechnology? For starters, AI fits in neatly with the dichotomous nature of biotechnology. After all, the technology contains a duality of its own—machine-like efficiency combined with the quaintly animalistic unpredictability in the way it works. In general terms, businesses and experts involved in biotechnology use AI to improve the quality of research and for improving compliance with regulatory standards.

More specifically, AI improves data capturing, analysis and pattern recognition in the following biotechnology-based applications:

https://youtube.com/watch?v=ZTZ1T9VBa-Y

Now their company, Sanas, is testing out artificial intelligence-powered software that aims to eliminate miscommunication by changing people’s accents in real time. A call center worker in the Philippines, for example, could speak normally into the microphone and end up sounding more like someone from Kansas to a customer on the other end.

Call centers, the startup’s founders say, are only the beginning. The company’s website touts its plans as “Speech, Reimagined.”

Continue reading “These former Stanford students are building an app to change your accent” »

Yiran Sherry’s waters broke while the family was stuck in traffic. With contractions increasing rapidly and traffic barely moving, the couple realized they were not going to make it in time.

Keating Sherry placed the vehicle on autopilot after setting the navigation system to the hospital, 20 minutes away in the western suburb of Paoli.

He said he laid one hand gently on the car’s steering wheel as he attended to his wife.

In 1971, scientists turned to genetics to control disease-spreading mosquitoes without DDT. Today, there are a variety of pesticide-free methods.

Join us on Patreon!
https://www.patreon.com/MichaelLustgartenPhD

Levine’s Biological age calculator is embedded as an Excel file in this link from my website:
https://michaellustgarten.com/2019/09/09/quantifying-biological-age/

Health — operanewsapp.

In this short video, filmed at ASTRO 2021, Siemens Healthineers’ Gabriel Haras introduces the company’s portfolio of artificial intelligence (AI)-based products. Such technologies support the entire care pathway for cancer patients, from screening and diagnostics to treatment and follow-up, including innovations such as AI-based autocontouring and generation of synthetic CT from an MRI scan for radiotherapy planning.

Next, Varian’s Kevin O’Reilly comments on the combining of Varian and Siemens Healthineers into one united company. He notes that the integration of AI capabilities has increased Varian’s ability to innovate, and will help accelerate its intelligent cancer care strategy: accelerating the path to treatment, increasing global access to care, exploiting data-driven insight and improving personalization.

2021 saw massive growth in the demand for edge computing — driven by the pandemic, the need for more efficient business processes, as well as key advances in the Internet of Things, 5G and AI.

In a study published by IBM in May, for example, 94 percent of surveyed executives said their organizations will implement edge computing in the next five years.

Continue reading “Top 5 Edge AI Trends to Watch in 2022” »

German drugmaker BioNTech is enrolling patients in a clinical trial to test its mRNA vaccine for colon cancer relapse.